Literature DB >> 9856508

Genetic testing for renal diseases: medical and ethical considerations.

R Marsick1, C Limwongse, E Kodish.   

Abstract

Advances in understanding the genetic basis of renal disorders will soon allow for the clinical use of genetic diagnostic testing. In this article, we review renal diseases with a known genetic basis and the current methods available for genetic testing. We then examine the potential medical indications for genetic testing, with special attention to autosomal dominant polycystic kidney disease (ADPKD). Because clinicians will be faced with patients considering genetic testing, we review the ethical considerations regarding genetic testing for renal diseases, recent genetic privacy legislation, and the special role genetic testing may have in transplantation. We conclude with a review of the necessary elements of informed consent, which provides the ethical foundation for patients deciding about genetic testing with the assistance of their physicians.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Year:  1998        PMID: 9856508     DOI: 10.1016/s0272-6386(98)70087-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical?

Authors:  Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

Review 2.  Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?

Authors:  Stéphanie De Rechter; Luc Breysem; Djalila Mekahli
Journal:  Front Pediatr       Date:  2017-12-20       Impact factor: 3.418

3.  Clinicians' attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease.

Authors:  Stéphanie De Rechter; Jonathan Kringen; Peter Janssens; Max Christoph Liebau; Koenraad Devriendt; Elena Levtchenko; Carsten Bergmann; François Jouret; Bert Bammens; Pascal Borry; Franz Schaefer; Djalila Mekahli
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.